Bangkok Genomics Innovation Public Company LimitedSET: BKGI🇹🇭 TH

Financial Information

Key Financial Highlights

As at 2026-09-30 · Unit: M.Baht

Item20242025H1 20269M 2026
Total revenue345.87386.73309.39455.04
Net profit50.1745.3562.1386.57
Total assets607.6701.86742.75754.08
Total liabilities68.44148.7155.56142.57
Shareholders' equity537.2551.23583.55607.99
EPS (Baht)0.090.080.10.14
ROE (%)12.988.3317.2319.84
ROA (%)11.637.5315.7617.88
Net profit margin (%)14.511.7220.0518.98
D/E (times)0.130.270.260.23
ItemY/E 2023Dec 2023Y/E 2024Dec 2024Y/E 2025Dec 20256M/2025Jun 20256M/2026Jun 2026
Cash And Cash Equivalents125.89199.91121.71220.12132.91
A/R Net29.3691.83311.57112.71281.78
Inventories10.0522.0936.0921.7778.93
Current Assets212.08514.92580.36504.79603.5
PP&E Net46.5755.4156.2451.8265.2
Non-Current Assets80.9492.67121.589.58139.25
Total Assets293.02607.6701.86594.38742.75
OD—————
A/P Net30.740.96119.4946.83125.16
Current portion of LT—4.21———
Current Liabilities35.5645.68126.8251.81135.47
Non-Current Liabilities21.6422.7621.8820.9720.08
Total Liabilities57.268.44148.772.78155.56
Authorized Capital300300300300300
Paid-Up Capital220300300300300
Premium (Discount) on Share Capital—171.21171.21171.21171.21
Retained Earnings (Deficit)16.1266.381.6948.76113.83
Treasury Stock—————
Shares Of The Company Held By Subsidiaries—————
Other Components Of Equity-0.31-0.31-1.68-0.31-1.49
- Surplus (Deficits)————0.19
Shareholders' Equity235.82537.2551.23519.67583.55
Minority Interest—1.951.931.933.64

Auditor's Reports

ReportDate of submissionAuditor’s opinionAuditor’s firm
Q2 /202614 Aug 2026Unqualified opinionDR. VIRACH AND ASSOCIATES COMPANY LIMITED
Q1 /202614 May 2026Unqualified opinionDR. VIRACH AND ASSOCIATES COMPANY LIMITED
Yearly 202525 Feb 2026Unqualified opinionDR. VIRACH AND ASSOCIATES COMPANY LIMITED
Q3 /202510 Nov 2025Unqualified opinionDR. VIRACH AND ASSOCIATES COMPANY LIMITED